IFNA2 and hairy cell leukemia: After IFN-α2b therapy, serum neutralizing antibodies were detected in 0% (0/90) of Hairy Cell Leukemia patients, 4% (1/24) of patients with AIDS-related Kaposi’s Sarcoma and <3% of patients with other malignancies (Intron-A® package insert).